The program has yet to reach magnet status among cheaper, youthful patients.
Eli Lilly and Boehringer Ingelheim submit a glargine biosimilar to the EMA; Novartis pipeline claims an Enbrel-superior treatment; Activartis med gets orphan drug status; generics makers may have to pay more attention to labels; Administration tweaks healthcare reform implementation over the long weekend.
For a country bent on healthcare cost control, findings represent an opportunity: authors say nearly 8% of the nation's total outlay could have been avoided.
Amgen and Astellas team up to take on Japan; GSK acquires Swiss vaccine developer's innovative platform; Ireland makes generic switches easier; Novo backs wet AMD therapy; Nike ditches Livestrong
The agency is revisiting the impact DTC advertising can have on healthcare. What's new: NPs and PAs are being asked for input.
From FDA and pharma, to Caronia and off-label communication, three healthcare policy experts offer their take on what 2013 holds in store.
Barack Obama edged Mitt Romney in fundraising from pharmas in the 2012 election, even as the industry favored Republicans in other contests. Were change-weary drug companies voting for the status quo?
No sector of the healthcare industry is rooting harder for the Supreme Court to overturn the Affordable Care Act completely tomorrow than are medical device companies, which are bracing themselves for a substantial excise tax on their revenues that takes effect next year under the law.
Congressional Republicans are trumpeting a cache of emails that give a glimpse into how the White House's deal with the pharma industry on healthcare reform came together. There's not much 'there' there, but there are some titillating glimpses into the legislative sausage factory.
Congressional Republicans -- and even a few Democrats -- are pressing the attack on the Independent Payment Advisory Board for Medicare, a part of the Affordable Care Act opposed by both PhRMA and the AMA.